Status | Study |
Not yet recruiting |
Study Name: Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I and II Condition: Mucopolysaccharidosis I Mucopolysaccharidosis II Date: 2017-05-11 Interventions: Drug: Adalimumab Injection [Humira] |
Recruiting |
Study Name: A Study of JR-141 in Patients With Mucopolysaccharidosis Type II Condition: Mucopolysaccharidosis II Date: 2017-04-10 Interventions: Drug: JR-141 IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week |
Recruiting |
Study Name: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II Condition: Mucopolysaccharidosis II Date: 2017-01-13 Interventions: Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor |
Not yet recruiting |
Study Name: Study of Idursulfase-beta (GC1111) in Hunter Syndrome Condition: Mucopolysaccharidosis II Date: 2016-01-17 Interventions: Biological: idursulfase beta I |
Recruiting |
Study Name: Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Condition: Hunter Syndrome Date: 2015-05-20 Interventions: Drug: Elaprase for intravenous (IV) infusion Patients enrolled in this study will receive once-weekly IV |
Enrolling by invitation |
Study Name: Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 Condition: Hunter Syndrome Date: 2015-04-01 Interventions: Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m |
Recruiting |
Study Name: Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome Condition: Mucopolysaccharidosis II Date: 2014-10-02 Interventions: Drug: AGT-182 Recombinant HIRMAb-IDS |
Terminated |
Study Name: Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project) Condition: Mucopolysaccharidosis Mucopolysaccharidosis I Date: 2014-03-20 |
Recruiting |
Study Name: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients Condition: Hunter Syndrome Date: 2014-01-19 |
Active, not recruiting |
Study Name: Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Condition: Hunter Syndrome Date: 2014-01-17 Interventions: Biological: idursulfase-IT 10m |